A new device designed to ‘revolutionise’ depression therapy has received CE mark approval and is now available across Europe.
Medical device group Magstim is using a non-invasive method which uses a series of repetitive brief and highly focussed magnetic pulses to stimulate brain cells.
The company has combined Transcranial Magnetic Stimulation (TMS) with its Horizon Performance platform to deliver treatment to patients without the side effects associated with medication or more invasive treatments.
Electrical activity in certain areas of the brain is thought to be reduced in patients with depression. Magstim’s Horizon Performance platform uses a focused electromagnetic coil to rapidly pulse a magnetic field to the targeted area of the brain. The platform induces a small electrical current which stimulates targeted brain cells into activity, potentially reducing symptoms of depression.
TMS is increasingly being used by practitioners in cases where antidepressant medication is proving ineffective and before invasive treatments like Electroconvulsive Therapy (ECT) are considered.